EUCTR2020-000712-30-NL进行中（未招募）1 期
Targeted glucocorticoid administration to improve safety learning in PTSD patients with HPA axis dysregulation - CovoS
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Radboudumc
- 入组人数
- 190
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patient group:
- •Participants with PTSD (n = 160), or suspected diagnosis, who will start trauma-focused therapy, will be recruitedbefore the start of their treatment at collaborating treatment centres. Patients must be aged 18-64. The expectedwaiting time until treatment is sufficient for participation, at least for part A of the study. Inclusion of patients intosubstudy B follows a selection procedure based on HPA axis dysregulation and feasibility.
- •Control group:
- •Healthy, non-trauma exposed control participants (n = 30) will be recruited from the general population in and around Nijmegen. Control participants only complete assessments from substudy A. Control participants must be aged 18-64 years. Inclusion criteria are no history of psychiatric disorders, and no history of childhood maltreatment. Hence, this group will reflect a healthy, non-trauma exposed control group, Control participants will be selected based on age, gender and education, with the aim to match the distributions of these relevant basic demographic variables to the (expected) distributions of the included patient group.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 190
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patient group:
- •Current episode of psychotic or manic symptoms.
- •Daily intake of benzodiazepines, or otherwise irregular intake of benzodiazepines (when needed”) but unable to withhold intake from the day prior to each test session until the end of the each test session. An exception is made for low doses of short-acting benzodiazepines that are prescribed for insomnia (i.e. as sleep medication).
- •A relevant neurological disorder (e.g., stroke, epilepsy, Multiple Sclerosis) or severe physical disorder which is likely to impact assessment procedures or results.
- •Reports to be unable or unwilling to withhold recreational drug use and limit alcohol use from the day prior to each test session until the end of the each test session.
- •General learning disability, or known to have intelligence Quotient (IQ) < 80
- •Body Mass Index (BMI) of >30.
- •Current or recent endocrine treatment (<1 month ago; for e.g., phechromocytoma, hyperthyroidism, Cushing’s syndrome).
- •Current or recent regular use of corticosteroids (<1 month ago).
- •For women: Pregnancy.
- •Reports hypersensitivity to hydrocortisone or any of the tablet’s auxiliary agents.
- •(Only for part B) Contraindications for MRI scanning (e.g., pacemaker, implanted metal parts, metal in or around the body, deep brain stimulation, severe claustrophobia).
- •Note: based on the exclusion criteria above, it may be decided by the research team that a participant should onlyparticipate in part A of the study, but will be excluded from part B of the study
- •Control group:
- •History of childhood maltreatment
- •Current or past psychiatric disorder
- •Use of psychotropic medication
- •Relevant neurological disorder (e.g., stroke, epilepsy, Multiple Sclerosis) or severe physical disorder which is likely to impact assessment procedures or results.
- •Reports to be unable or unwilling to withhold recreational drug use and limit alcohol use from the day prior to each test session until the end of the each test session.
- •General learning disability, or known to have intelligence Quotient (IQ) < 80
- •Body Mass Index (BMI) of >30.
- •Current or recent endocrine treatment (<1 month ago; for e.g., phechromocytoma, hyperthyroidism, Cushing’s syndrome).
- •Current or recent regular use of corticosteroids (<1 month ago).
- •For women: Pregnancy.
研究者
相似试验
招募中
3 期
Targeted glucocorticoid administration to improve safety learning in PTSD patients with HPA axis dysregulatioNL-OMON52772Radboud Universitair Medisch Centrum190
进行中（未招募）
不适用
ocal Glucocorticoid Injektion in the Treatment of Benign Oesophageal Strictures, a Randomized Clinical StudyPatients with benign oesophageal strictures and symptoms where dilatation of the stricture is planned.MedDRA version: 8.1Level: LLTClassification code 10030199Term: Oesophageal strictureEUCTR2006-005856-33-SEThe Department of Molecular Medicin and Surgery, P9:03, Karolinska Institutet60
已完成
不适用
Effect of glucocorticoids for improving quality of recovery after general anesthesia: A systematic review and meta-analysisPatients who undergo general anesthesiaJPRN-UMIN000015678Kanagawa Childrens Medical Center
招募中
4 期
BLISS-POSTSystemic Lupus ErythematosusJPRN-jRCTs071190045Tanaka Yoshiya100
尚未招募
不适用
Glucocorticoid-tapering aimed maintenance therapy in patients with systemic lupus erythematosussystemic lupus erythematosusJPRN-UMIN000031259First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan100